K2 Therapeutics, a Flagship-style ‘hub-and-spoke’ biotech that in-licenses drug candidates worldwide, named the former Legend Biotech chief as its new leader.
Dutch researchers found that low-dose digoxin — a drug derived from foxglove and costing pennies a day — reduced heart-failure hospitalizations by about 25% in a large placebo-controlled trial.
Otsuka's centanafadine is the first ADHD medicine to block reuptake of all three key neurotransmitters — a new mechanism for adults and children 6 and up.
Reported delays in delivering Nexviazyme — an enzyme therapy for a rare, progressive disease — follow an FDA warning letter over a Sanofi manufacturing site.
Altimmune's pemvidutide reduced heavy-drinking days more than placebo in a Phase 2 study — early evidence that GLP-1-class drugs may curb more than appetite.
After a string of research setbacks, Biohaven traded its most advanced medicine for upfront cash and future royalties — an unusual move to part with a key asset just before pivotal data.
By re-lengthening a shortened RNA, scientists restored the molecular flag that lets immune cells see prostate tumors — turning on checkpoint therapy that usually fails.
Researchers paired live malaria parasites with a drug that stops them in the liver, converting infectious bites into immunizing events that produced durable protection in animals.
The revenue-cycle giant is adding an AI platform that files and clears insurer authorizations — targeting one of the most-hated bottlenecks in US healthcare.
The deal feeds full-text biomedical research to an AI used by a dozen of the world's top 20 drugmakers — the latest sign of AI reshaping how drugs are found.
Ultragenyx’s Genglycos delivers a working gene to the liver in glycogen storage disease type Ia, aiming to free patients from the relentless routine of round-the-clock cornstarch dosing.
Studying human brains — including healthy centenarians — scientists found a moment when microglia switch from helpful to harmful, shaping Alzheimer's outcomes.